Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En studie for å vurdere effekt og sikkerhet for Empasiprubart versus IVIG hos voksne med CIDP (emvigorate)

2. november 2026 oppdatert av: argenx

En fase 3, randomisert, dobbeltblindet, dobbelt-dummy studie som evaluerer effektiviteten og sikkerheten til intravenøs empasiprubart versus intravenøs immunoglobulin hos voksne med kronisk inflammatorisk demyeliniserende polyneuropati

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).

More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

218

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Córdoba, Argentina, X5004AOA
        • Rekruttering
        • Instituto Privado Kremer
        • Ta kontakt med:
      • Rosario, Argentina, S2000DTP
        • Rekruttering
        • INECO Neurociencias Oroño
        • Ta kontakt med:
    • New South Wales
      • Liverpool, New South Wales, Australia, 2179
        • Rekruttering
        • Liverpool Hospital
        • Ta kontakt med:
      • Salvador, Brasil, 40290-000
        • Rekruttering
        • Escola Bahiana de Medicina e Saude Publica
        • Ta kontakt med:
      • São Paulo, Brasil, 04038-002
        • Rekruttering
        • PSEG Centro de Pesquisa Clinica
        • Ta kontakt med:
    • São Paulo
      • São Paulo, São Paulo, Brasil, 04038-002
        • Rekruttering
        • PSEG Centro de Pesquisa Clinica - Rua Borges Lagoa 1060
        • Ta kontakt med:
      • Edmonton, Canada, T6G 2G3
        • Rekruttering
        • University of Alberta
        • Ta kontakt med:
    • Alberta
      • Calgary, Alberta, Canada, T2N 1N4
        • Rekruttering
        • University of Calgary
        • Ta kontakt med:
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z2C7
        • Rekruttering
        • Black Tusk Research Group
        • Ta kontakt med:
      • Bogotá, Colombia, 110231
        • Rekruttering
        • Hospital Universitario San Ignacio
        • Ta kontakt med:
      • Medellín, Colombia, 50012
        • Rekruttering
        • Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico
        • Ta kontakt med:
      • Medellín, Colombia, 50012
        • Rekruttering
        • Hospital Alma Máter de Antioquia
        • Ta kontakt med:
      • Tallinn, Estland, 11315
      • Tartu, Estland, 50406
        • Rekruttering
        • Tartu University Hospital
        • Ta kontakt med:
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • University of Alabama
        • Ta kontakt med:
          • Eroboghene Ubogu, MD
          • Telefonnummer: 857-350-4834
          • E-post: ubogu@uab.edu
    • Arizona
      • Tucson, Arizona, Forente stater, 85719-4330
        • Rekruttering
        • Banner University of Arizona Medical Center
        • Ta kontakt med:
    • California
      • Rancho Mirage, California, Forente stater, 922701
        • Rekruttering
        • Samir Macwan, M.D., Inc.
        • Ta kontakt med:
    • Colorado
      • Colorado Springs, Colorado, Forente stater, 80907
        • Rekruttering
        • Colorado Springs Neurological Associates
        • Ta kontakt med:
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Rekruttering
        • MedStar Washington Hospital Center
        • Ta kontakt med:
    • Florida
      • Homestead, Florida, Forente stater, 33033
      • Miami, Florida, Forente stater, 33133
        • Rekruttering
        • Visionary Investigators Network
        • Ta kontakt med:
      • Tampa, Florida, Forente stater, 33616
        • Rekruttering
        • University of South Florida
        • Ta kontakt med:
    • Kentucky
      • Nicholasville, Kentucky, Forente stater, 40356-6066
        • Rekruttering
        • Baptist Health Medical Group Neurology
        • Ta kontakt med:
    • Louisiana
      • Slidell, Louisiana, Forente stater, 70458
        • Rekruttering
        • Paradigm Health System
        • Ta kontakt med:
    • Maryland
      • Columbia, Maryland, Forente stater, 21044
        • Rekruttering
        • Erlanger Health System
        • Ta kontakt med:
    • Michigan
      • Ann Arbor, Michigan, Forente stater, 48109
        • Rekruttering
        • University of Michigan Hospital
        • Ta kontakt med:
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45267-2827
        • Rekruttering
        • University of Cincinnati Health
        • Ta kontakt med:
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Rekruttering
        • Jefferson Health Honickman Center
        • Ta kontakt med:
      • Philadelphia, Pennsylvania, Forente stater, 19104-5127
        • Rekruttering
        • Perelman Center for Advanced Medicine
        • Ta kontakt med:
    • Tennessee
      • Knoxville, Tennessee, Forente stater, 37909
        • Rekruttering
        • University Neurology
        • Ta kontakt med:
    • Texas
      • Houston, Texas, Forente stater, 77094
      • Irving, Texas, Forente stater, 75063
        • Rekruttering
        • National Neuromuscular Research Institute
        • Ta kontakt med:
      • Bordeaux, Frankrike, 33076
      • Le Kremlin-Bicêtre, Frankrike, 94270
        • Rekruttering
        • AP-HP - Hôpital Bicêtre
        • Ta kontakt med:
      • Nice, Frankrike, 6001
        • Rekruttering
        • CHU de Nice-Hôpital Pasteur
        • Ta kontakt med:
      • Strasbourg, Frankrike, 67200
        • Rekruttering
        • CHU de Strasbourg - Hôpital de Hautepierre
        • Ta kontakt med:
      • Toulouse, Frankrike, 31059
        • Rekruttering
        • CHU de Toulouse-Hôpital Pierre-Paul Riquet-Site de Purpan
        • Ta kontakt med:
    • Bouches-du-Rhone
      • Marseille, Bouches-du-Rhone, Frankrike, 13005
        • Rekruttering
        • AP-HM- Hôpital de La Timone
        • Ta kontakt med:
    • Paris
      • Paris, Paris, Frankrike, 75013
        • Rekruttering
        • AP-HP - Hôpital de la Pitié Salpétrière
        • Ta kontakt med:
      • Athens, Hellas, 15562
        • Rekruttering
        • University General Hospital of Alexandroupolis
        • Ta kontakt med:
      • Chaïdári, Hellas, 124 62
        • Rekruttering
        • University General Hospital ''ATTIKON'' - General Hospital of West Attica H AGIA VARVARA
        • Ta kontakt med:
      • Ashkelon, Israel, 78278
        • Rekruttering
        • The Barzilai University Medical Center
        • Ta kontakt med:
      • Jerusalem, Israel, 9112001
        • Rekruttering
        • Hadassah Medical Center- Ein Kerem
        • Ta kontakt med:
      • Tel HaShomer, Israel, 52621
      • Bologna, Italia, 40139
        • Rekruttering
        • AUSL di Bologna - Ospedale Bellaria
        • Ta kontakt med:
      • Pavia, Italia, 27100
        • Rekruttering
        • Fondazione Istituto Neurologico Nazionale Casimiro Mondino IRCCS
        • Ta kontakt med:
      • Roma, Italia, 133
        • Rekruttering
        • Fondazione PTV Policlinico Tor Vergata
        • Ta kontakt med:
      • Roma, Italia, 161
        • Rekruttering
        • Azienda Ospedaliero-Universitaria Policlinico Umberto I
        • Ta kontakt med:
      • Roma, Italia, 00189
      • Rozzano, Italia, 20089
        • Rekruttering
        • IRCCS Istituto Clinico Humanitas
        • Ta kontakt med:
          • Pietro Emiliano Doneddu, MD
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italia, 40139
        • Rekruttering
        • AUSL di Bologna - Ospedale Bellaria
        • Ta kontakt med:
      • Aomori, Japan, 030-8553
      • Bunkyō City, Japan, 113-8431
        • Rekruttering
        • Juntendo University Hospital
        • Ta kontakt med:
      • Chūōku, Japan, 260-8677
        • Rekruttering
        • Chiba University Hospital
        • Ta kontakt med:
      • Hiroshima, Japan, 430-8558
        • Rekruttering
        • Seirei Hamamatsu Hospital
        • Ta kontakt med:
      • Izunokuni, Japan, 410-2295
        • Rekruttering
        • Juntendo Shizuoka University Hospital
        • Ta kontakt med:
      • Osaka, Japan, 545-8586
        • Rekruttering
        • Osaka Metropolitan University Hospital
        • Ta kontakt med:
      • Saga, Japan, 849-8501
        • Rekruttering
        • Saga University Hospital
        • Ta kontakt med:
      • Shimotsuke, Japan, 329-0498
        • Rekruttering
        • Jichi Medical University Hospital
        • Ta kontakt med:
      • Tsuchiura, Japan, 300-0028
        • Rekruttering
        • General Hospital Tsuchiura Kyodo Hospital
        • Ta kontakt med:
      • Ube, Japan, 755-0067
      • Utrecht, Nederland, 3584 CX
        • Rekruttering
        • Universitair Medisch Centrum Utrecht
        • Ta kontakt med:
      • Oslo, Norge, 450
        • Rekruttering
        • Oslo Universitetssykehus HF, Ullevål
        • Ta kontakt med:
      • Bydgoszcz, Polen, 85-065
        • Rekruttering
        • MICS Centrum Medyczne Bydgoszcz
        • Ta kontakt med:
      • Bydgoszcz, Polen, 85-796
        • Rekruttering
        • Neurocentrum Bydgoszcz
        • Ta kontakt med:
      • Katowice, Polen, 40-689
      • Krakow, Polen, 30-721
        • Rekruttering
        • Centrum Medyczne Linden
        • Ta kontakt med:
      • Krakow, Polen, 30-688
        • Rekruttering
        • SP ZOZ Szpital Uniwersytecki w Krakowie
        • Ta kontakt med:
      • Lublin, Polen, 20-064
        • Rekruttering
        • Galen Clinic - Lublin
        • Ta kontakt med:
      • Poznan, Polen, 61-731
        • Rekruttering
        • Clinical Research Center Sp. z o.o. Medic-R sp.k.
        • Ta kontakt med:
      • Rzeszów, Polen, 35-210
        • Rekruttering
        • Centrum Medyczne Medyk
        • Ta kontakt med:
      • Rzeszów, Polen, 35-210
        • Rekruttering
        • Centrum Medyczne Medyk-al. Tadeusza Rejtana 53
        • Ta kontakt med:
      • Szczecin, Polen, 71-252
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny Nr 1
        • Ta kontakt med:
      • Szczecin, Polen, 71-252
        • Rekruttering
        • Uniwersytecki Szpital Kliniczny Nr 1 im. Tadeusza Sokolowskiego Pomorskiego UM w Szczecinie
        • Ta kontakt med:
      • Warsaw, Polen, 02-097
        • Rekruttering
        • Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
        • Ta kontakt med:
      • Porto, Portugal, 4050-342
        • Rekruttering
        • ULS de Santo António, EPE - Hospital de Santo António
        • Ta kontakt med:
      • Bucharest, Romania, 41914
        • Rekruttering
        • Institutul National de Neurologie si Boli Neurovasculare Bucuresti
        • Ta kontakt med:
      • Constanța, Romania, 900348
        • Rekruttering
        • Brainaxy Clinic SRL
        • Ta kontakt med:
      • Târgu Mureş, Romania, 540136
        • Rekruttering
        • Targu-Mures Emergency Clinical County Hospital
        • Ta kontakt med:
    • Bucharest
      • Bucharest, Bucharest, Romania, 41914
        • Rekruttering
        • Institutul National de Neurologie si Boli Neuroavasculare Bucuresti
        • Ta kontakt med:
      • Belgrade, Serbia, 11000
        • Rekruttering
        • University Clinical Center of Serbia - Dr Subotica 6
        • Ta kontakt med:
      • Niš, Serbia, 18 000
        • Rekruttering
        • University Clinical Center Nis
        • Ta kontakt med:
      • Singapore, Singapore, 308433
      • Martin, Slovakia, 036 59
        • Rekruttering
        • Univerzitna nemocnica MARTIN
        • Ta kontakt med:
      • Ljubljana, Slovenia, 1000
        • Rekruttering
        • University Medical Centre Ljubljana
        • Ta kontakt med:
      • Maribor, Slovenia, 2000
        • Rekruttering
        • University Clinical Centre Maribor
        • Ta kontakt med:
      • Barcelona, Spania, 08041
        • Rekruttering
        • Hospital de La Santa Creu i Sant Pau
        • Ta kontakt med:
      • Madrid, Spania, 28007
        • Rekruttering
        • Hospital General Universitario Gregorio Marañon
        • Ta kontakt med:
      • Sant Andreu de la Barca, Spania, 08740
        • Rekruttering
        • Hospital Universitario Vall d'Hebron
        • Ta kontakt med:
      • Seville, Spania, 41009
        • Rekruttering
        • Hospital Universitario Virgen Macarena
        • Ta kontakt med:
      • Leeds, Storbritannia, LS1 3EX
      • London, Storbritannia, WC1N 3BG
        • Rekruttering
        • The National Hospital for Neurology and Neurosurgery - PPDS
        • Ta kontakt med:
    • Lancashire
      • Salford, Lancashire, Storbritannia, M6 8HD
        • Rekruttering
        • Salford Royal Hospital - PPDS
        • Ta kontakt med:
      • Geneva, Sveits, 1205
        • Rekruttering
        • Hôpitaux Universitaires de Genève (HUG)
        • Ta kontakt med:
      • Gothenburg, Sverige, 41346
        • Rekruttering
        • Sahlgrenska University Hospital
        • Ta kontakt med:
      • Busan, Sør -Korea, 48108
        • Rekruttering
        • Inje University Haeundae Paik Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • Seoul National University Hospital
        • Ta kontakt med:
      • Seoul, Sør -Korea, 05030
        • Rekruttering
        • Konkuk University Medical Center
        • Ta kontakt med:
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Severance Hospital Yonsei University Health System
        • Ta kontakt med:
      • Brno, Tsjekkia
        • Rekruttering
        • Fakultni nemocnice Brno
        • Ta kontakt med:
      • Istanbul, Tyrkia (Türkiye), 34083
        • Rekruttering
        • Istanbul Tip Fakultesi Hastanesi (Istanbul Universitesi)
        • Ta kontakt med:
      • Samsun, Tyrkia (Türkiye), 55200
        • Rekruttering
        • Ondokuz Mayis Universitesi Saglik Uygulama ve Arastirma Merkezi
        • Ta kontakt med:
      • Berlin, Tyskland, 13353
        • Rekruttering
        • Charité - Universitätsmedizin Berlin
        • Ta kontakt med:
      • Kiel, Tyskland, 24105
        • Rekruttering
        • Universitätsklinikum Schleswig-Holstein - Campus Kiel
        • Ta kontakt med:
      • Budapest, Ungarn, 1085
        • Rekruttering
        • Semmelweis Egyetem Genomikai Medicina és Ritka Betegségek Intézete
        • Ta kontakt med:
      • Linz, Østerrike
        • Rekruttering
        • Kepler Universitätsklinikum Linz - Med Campus III
        • Ta kontakt med:
      • Vienna, Østerrike, 1090
        • Rekruttering
        • Universitätsklinikum AKH Wien
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Has either typical CIDP or 1 of the following CIDP variants: motor CIDP, multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP
  • Has responded to IVIg in the past 5 years
  • Receiving treatment with IVIg within a standard optimal maintenance dosing regimen, with a minimum weekly IVIg dose of at least 0.125 g/kg
  • Has residual disability and active disease

Exclusion Criteria:

  • Besides the indication under study, known autoimmune disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP or puts the participant at undue risk, including polyneuropathy of other causes
  • Meets the criteria for possible or sensory CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021)
  • Use of other long-acting immunomodulatory treatment

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Part A - empasiprubart + IVIg-placebo

During Part A, participants receive empasiprubart and a placebo resembling the IVIg treatment in this arm.

A placebo resembling the IVIg treatment

Intravenous infusion of empasiprubart

Aktiv komparator: Part A - IVIg + empasiprubart-placebo

During Part A, participants receive IVIg and a placebo resembling the empasiprubart treatment in this arm.

Intravenous infusion of IVIg

A placebo resembling the empasiprubart treatment

Eksperimentell: Part B - empasiprubart

After completion of part A, participants can proceed to part B where they receive empasiprubart (no IVIg). Participants from the empasiprubart + IVIg- placebo arm in Part A will receive empasiprubart placebo once to maintain the blind of Part A.

Intravenous infusion of empasiprubart

A placebo resembling the empasiprubart treatment

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Reduction of ≥1 point compared with baseline in aINCAT score at week 24
Tidsramme: up to 24 weeks

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

up to 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Prosentandel av planlagte timer tapt totalt (fravær+ presentisme)
Tidsramme: opptil 24 uker
opptil 24 uker
Forekomst av antidrug Antistoffer mot Empasiprubart i serum
Tidsramme: Opptil 24 uker (del A) + 96 uker (del B)
Opptil 24 uker (del A) + 96 uker (del B)
Forekomst av nøytraliserende antistoffer mot empasiprubart i serum
Tidsramme: Opptil 24 uker (del A) + 96 uker (del B)
Opptil 24 uker (del A) + 96 uker (del B)
Forekomst av (alvorlige) bivirkninger
Tidsramme: Opptil 24 uker (del A) + 96 uker (del B)
Opptil 24 uker (del A) + 96 uker (del B)
Prosentvis endring fra baseline i gratis C2 og total C2 over tid
Tidsramme: Opptil 24 uker (del A) + 96 uker (del B)
Opptil 24 uker (del A) + 96 uker (del B)
Serumkonsentrasjoner av empasiprubart over tid
Tidsramme: Opptil 24 uker (del A) + 96 uker (del B)
Opptil 24 uker (del A) + 96 uker (del B)
Change from baseline in I-RODS centile points score at week 24
Tidsramme: up to 24 weeks

Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP. The score ranges from 0 to 100 (higher score, worse outcome).

up to 24 weeks
Change from baseline in MRC-SS at week 24
Tidsramme: up to 24 weeks

The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome).

up to 24 weeks
Change from baseline in grip strength (3-day moving average) in the dominant hand at week 24
Tidsramme: up to 24 weeks

The grip strength will be measured daily by using a Martin-Vigorimeter. The 3 daily measurements of grip strength from the left hand and the 3 daily measurements of grip strength from the right hand will be recorded, and the daily average for the left hand and right hand will be calculated, respectively. The 3-day moving average will be generated based on the average of the obtained averages for each hand on the target day and the preceding 2 days.

up to 24 weeks
Time to reduction of ≥1 point from baseline in aINCAT score
Tidsramme: up to 24 weeks

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

up to 24 weeks
Change from baseline in TUG at week 24
Tidsramme: up to 24 weeks

The Timed Up and Go Test (TUG) is a simple test to assess a person's mobility in which the time expended to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down is measured.

up to 24 weeks
Time to increase of ≥1 point compared with baseline in aINCAT score
Tidsramme: Up to 24 weeks

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

Up to 24 weeks
Change from baseline in grip strength (3-day moving average) of both hands over time
Tidsramme: up to 24 weeks + 96 weeks (Part B)

The grip strength will be measured daily by using a Martin-Vigorimeter. The 3 daily measurements of grip strength from the left hand and the 3 daily measurements of grip strength from the right hand will be recorded, and the daily average for the left hand and right hand will be calculated, respectively. The 3-day moving average will be generated based on the average of the obtained averages for each hand on the target day and the preceding 2 days.

up to 24 weeks + 96 weeks (Part B)
Change from baseline in grip strength (daily average) for both hands
Tidsramme: up to 24 weeks + 96 weeks (Part B)

The grip strength will be measured daily by using a Martin-Vigorimeter. The 3 daily measurements of grip strength from the left hand and the 3 daily measurements of grip strength from the right hand will be recorded, and the daily average for the left hand and right hand will be calculated, respectively. A daily average will be generated based on the average of the obtained averages for each hand.

up to 24 weeks + 96 weeks (Part B)
Change from baseline in MRC-SS over time
Tidsramme: up to 96 weeks (Part B)

The Medical Research Council Sum Score evaluates motor strength. Evaluated on 6 muscle groups on each side, the score varies from 0 to 60 (lower score, worse outcome).

up to 96 weeks (Part B)
Change from baseline in aINCAT over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

The Adjusted Inflammatory Neuropathy Cause and Treatment Disability Score (aINCAT) score is a 10-point scale that covers the functionality of legs and arms. The score varies between 0 and 10 (higher score, worse outcome).

up to 24 weeks (Part A) + 96 weeks (Part B)
Change from baseline in EQ-5D-5L over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

EQ-5D-5L questionnaire is a patient-reported outcome measure, ranging 0 to 100 (lower score, worse outcome).

up to 24 weeks (Part A) + 96 weeks (Part B)
Change from baseline in RT-FSS over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

Rasch-Transformed Fatigue Severity Scale (RT-FSS) is a patient-reported outcome measure to distinguish fatigue from clinical depression.

up to 24 weeks (Part A) + 96 weeks (Part B)
Change from baseline in SF-12 over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

12-Item Short Form Health Survey (SF-12) is a general patient-reported outcome measure.

up to 24 weeks (Part A) + 96 weeks (Part B)
Change from baseline in BPI-SF over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

The Brief Pain Inventory-Short Form (BPI-SF) is a patient-reported outcome measure to assess pain severity and pain interference.

up to 24 weeks (Part A) + 96 weeks (Part B)
PGI-S values over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

The Patient Global Impression of Severity (PGI-S) is a patient-reported outcome measure that reflects the patient's belief about the severity of the illness.

up to 24 weeks (Part A) + 96 weeks (Part B)
PGI-C values over time
Tidsramme: up to 24 weeks (Part A) + 96 weeks (Part B)

The Patient Global Impression of Change (PGI-C) is a patient- reported outcome measure that reflects the patient's belief about the efficacy of treatment.

up to 24 weeks (Part A) + 96 weeks (Part B)
Values for work-related and household chore activities of the HRPQ
Tidsramme: up to 24 weeks

The Health-Related Productivity Questionnaire (HRPQ) assesses health-related and work-related productivity, with questions related to 'hours lost because of absenteeism'.

up to 24 weeks
Change from baseline in I-RODS centile points score over time
Tidsramme: Up to 96 weeks (Part B)

Inflammatory Rasch-built Overall Disability Scale (I-RODS) assesses the limitations of activities and social participation in patients with inflammatory neuropathies like CIDP. The score ranges from 0 to 100 (higher score, worse outcome).

Up to 96 weeks (Part B)
Change from baseline in TUG over time
Tidsramme: Up to 96 weeks (Part B)

The Timed Up and Go Test (TUG) is a simple test to assess a person's mobility in which the time expended to rise from a chair, walk 3 meters, turn around, walk back to the chair, and sit down is measured.

Up to 96 weeks (Part B)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

22. august 2025

Primær fullføring (Antatt)

1. september 2027

Studiet fullført (Antatt)

1. september 2030

Datoer for studieregistrering

Først innsendt

26. mars 2025

Først innsendt som oppfylte QC-kriteriene

2. april 2025

Først lagt ut (Faktiske)

9. april 2025

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

3. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • ARGX-117-2401
  • 2024-520097-36-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .